日报更新时间：
周报更新时间：04-18 04:06
今开价：124.34
最高价：124.38
成交量：236599.0
昨收价：124.03
最低价：121.36
最新价：122.05
中文名称：Acceleron制药
英文名称：Acceleron Pharma
简介：Acceleron Pharma Inc.在特拉华州注册成立于2003年6月13日，凤凰制药公司，公司随后更名为加速子制药公司，并在2004年2月开始运营的公司是剑桥，马萨诸塞州的生物制药公司，专注于这是基于人体用来调节其细胞和组织的生长和修复的机制，新的治疗候选人的发现，开发和商业化
电话：1-617-6499200
Acceleron制药公司是一个临床阶段的生物制药公司，专注于发现、开发和商业化应用蛋白质疗法治疗癌症和罕见疾病的研究。公司与同行Celgene公司达成合作协议。公司的候选产品主要包括luspatercept和sotatercept，用于治疗ß地中海贫血症和骨髓增生异常综合征及其并发症等，目前处于III期临床试验阶段。同时，sotatercept也用于增加骨矿物质密度，治疗慢性肾脏疾病和末期肾脏疾病等。此外，Acceleron Pharma的候选产品dalantercept，可用于治疗肾细胞癌和肝癌。候选产品ACE-083用于促进肌肉生长和功能恢复以及治疗肌肉萎缩，处于一期临床试验阶段。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2019-07-15 | Veness (Adam M) | General Counsel | Sell | 538 | 40.71 |
| 2019-07-08 | Quisel John D | Officer | Buy | 2346 | 5.28 |
| 2019-07-08 | Quisel John D | Officer | Buy | 1562 | 7.12 |
| 2019-07-08 | Quisel John D | Officer | Buy | 5000 | 3.88 |
| 2019-06-27 | George (Jean M) | Director | Sell | 11812 | 41.17 |
| 2019-06-25 | George (Jean M) | Director | Buy | 11812 | -- |
| 2019-06-25 | George (Jean M) | Director | Buy | 7500 | 30.17 |
| 2019-06-25 | George (Jean M) | Director | Buy | 10000 | 27.97 |
| 2019-06-25 | George (Jean M) | Director | Sell | 25688 | 39.16 |
| 2019-06-25 | George (Jean M) | Director | Sell | 11812 | -- |
| 2019-06-25 | George (Jean M) | Director | Buy | 20000 | 24.11 |
| 2019-06-13 | Zakrzewski (Joseph S. JR) | Director | Buy | 5000 | 38.05 |
| 2019-06-04 | Veness (Adam M) | General Counsel | Buy | 1100 | -- |
| 2019-04-08 | Quisel John D | Chairman of the Board | Sell | 100 | 45.46 |
| 2019-04-08 | Quisel John D | Chairman of the Board | Sell | 70 | 44.24 |
| 2019-04-08 | Quisel John D | Chairman of the Board | Sell | 3452 | 44.62 |
| 2019-04-08 | McLaughlin (Kevin F) | Chief Financial Officer | Sell | 100 | 45.46 |
| 2019-04-08 | McLaughlin (Kevin F) | Chief Financial Officer | Sell | 11900 | 44.61 |
| 2019-04-08 | Kumar Ravindra | Officer | Sell | 100 | 45.46 |
| 2019-04-08 | Kumar Ravindra | Officer | Sell | 70 | 44.24 |
| 2019-04-08 | Kumar Ravindra | Officer | Sell | 3452 | 44.62 |
| 2019-04-08 | Dable (Habib J.) | Chief Executive Officer | Sell | 7214 | 44.60 |
| 2019-04-08 | Dable (Habib J.) | Chief Executive Officer | Sell | 146 | 44.23 |
| 2019-04-08 | Dable (Habib J.) | Chief Executive Officer | Sell | 100 | 45.46 |
| 2019-04-01 | McLaughlin (Kevin F) | Chief Financial Officer | Sell | 648 | 48.02 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Eagle Asset Management, Inc. | 878577 | 1.67% | 988 | 0.11% | 2019-03-31 |
| Farallon Capital Management, L.L.C. | 2375000 | 4.51% | 275000 | 13.10% | 2019-03-31 |
| Fidelity Management & Research Company | 2972145 | 5.64% | -8944 | -0.30% | 2019-07-31 |
| Fidelity SelectCo, LLC | 3155058 | 5.99% | -292700 | -8.49% | 2019-07-31 |
| Vanguard Group Inc | 4011248 | 7.61% | 488620 | 13.87% | 2019-03-31 |
| T. Rowe Price Associates, Inc. | 4495413 | 8.53% | -520254 | -10.37% | 2019-03-31 |
| BlackRock Inc | 4797511 | 9.11% | 368617 | 8.32% | 2019-03-31 |
| Fidelity Management and Research Company | 6356176 | 12.06% | 422871 | 7.13% | 2019-03-31 |
| FMR Inc | 7363953 | 13.98% | 435414 | 6.28% | 2019-03-31 |
| BlackRock Fund Advisors | 2008665 | 3.81% | 27948 | 1.41% | 2019-07-31 |
| State Street Corporation | 1840515 | 3.49% | 376334 | 25.70% | 2019-03-31 |
| Artal Group S A | 1650000 | 3.13% | 600000 | 57.14% | 2019-03-31 |
| TimesSquare Capital Management, LLC | 920715 | 1.75% | 209900 | 29.53% | 2019-03-31 |
| Fidelity Institutional Asset Management | 1007777 | 1.91% | 12543 | 1.26% | 2019-03-31 |
| Great Point Partners LLC | 1080113 | 2.05% | 43538 | 4.20% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 1247141 | 2.37% | 245 | 0.02% | 2019-07-31 |
| Deerfield Management Co | 1255174 | 2.38% | -131367 | -9.47% | 2019-03-31 |
| HHG PLC | 1310533 | 2.49% | 34346 | 2.69% | 2019-03-31 |
| Westfield Capital Management Company, LP | 1377123 | 2.61% | 84410 | 6.53% | 2019-03-31 |
| Wellington Management Company LLP | 1468279 | 2.79% | 1468279 | -- | 2019-03-31 |
| SSGA Funds Management Inc | 1003800 | 1.91% | 81 | 0.01% | 2019-05-31 |
| BlackRock Asset Management Canada Ltd | 1018738 | 1.93% | 17 | -- | 2019-05-31 |
| Perceptive Advisors LLC | 905017 | 1.72% | -623188 | -40.78% | 2018-12-31 |
| Geode Capital Management, LLC | 906926 | 1.73% | 485984 | 115.45% | 2018-12-31 |
| BlackRock Advisors LLC | 784937 | 1.52% | 10206 | 1.32% | 2019-02-28 |
| Hillhouse Capital Management, Ltd. | 813600 | 1.57% | 113600 | 16.23% | 2018-09-30 |
| Novo A/S | 1103937 | 2.39% | -450000 | -28.96% | 2018-06-30 |
| BlackRock Institutional Trust Company NA | 1156031 | 2.50% | 83250 | 7.76% | 2018-06-30 |
| Celgene Corp | 6118479 | 13.88% | 745592 | 13.88% | 2017-09-25 |
| State Street Corp | 1533710 | 3.35% | 68721 | 4.69% | 2018-06-30 |
| Eventide Asset Management, LLC | 529900 | 1.16% | -- | -- | 2018-06-30 |
| Janus Capital Management LLC | 506877 | 1.11% | 506877 | -- | 2018-06-30 |
| Pictet Asset Management SA | 496218 | 1.08% | -19855 | -3.85% | 2018-06-30 |
| Polar Capital LLP | 1072898 | 2.35% | 42898 | 4.16% | 2018-03-31 |
| Brown Investment Advisory Incorporated | 504677 | 1.10% | 28806 | 6.05% | 2018-03-31 |
| Goldman Sachs Asset Management LP | 495174 | 1.08% | -55881 | -10.14% | 2018-03-31 |
| Northern Trust Investments N A | 437397 | 0.96% | 371 | 0.08% | 2018-03-31 |
| Sectoral Asset Management Inc | 712356 | 1.57% | 107399 | 17.75% | 2017-12-31 |
| Citigroup Inc | 858293 | 1.93% | 830721 | 3012.92% | 2017-09-30 |
| Oak Ridge Investments, LLC | 1226468 | 3.25% | -115363 | -8.60% | 2016-09-30 |
| Granahan Investment Management Inc.. | 817149 | 2.17% | 57530 | 7.57% | 2016-09-30 |
| Morgan Stanley & Co Inc | 766138 | 2.03% | 763885 | 33905.24% | 2016-09-30 |
| LAURION CAPITAL MANAGEMENT LP | 690000 | 1.83% | 690000 | -- | 2016-09-30 |
| Qvt Financial LP | 636764 | 1.69% | -65646 | -9.35% | 2016-09-30 |
| Franklin Advisers Inc | 494777 | 1.31% | -- | -- | 2016-09-30 |
| Adage Capital Partners, L.P., and related funds | 1772406 | 3.00% | 67457772 | -- | 1999-11-30 |
| Terrance G. McGuire | 2580291 | 3.00% | 98205875 | 0.10% | 1999-11-30 |
| Celgene Corporation | 4572887 | 3.00% | 174044079 | 0.10% | 1999-11-30 |
| FMRLLC and affiliates | 4837978 | 3.00% | 184133443 | 0.20% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Fidelity | 344995 | 0.65% | -283 | -0.08% | 2019-06-30 |
| Vanguard Total Stock Market Index Fund | 1238083 | 2.35% | 298 | 0.02% | 2019-06-30 |
| Vanguard Small Cap Index | 1151160 | 2.18% | 6762 | 0.59% | 2019-06-30 |
| T. Rowe Price Health Sciences Fund | 1029587 | 1.95% | -297982 | -22.45% | 2019-06-30 |
| iShares Russell 2000 ETF | 995855 | 1.89% | 15535 | 1.58% | 2019-07-30 |
| BlackRock Health Sciences Opps Port | 786900 | 1.49% | -- | -- | 2019-06-30 |
| Carillon Eagle Small Cap Growth Fund | 657640 | 1.25% | -- | -- | 2019-06-30 |
| Vanguard Small Cap Growth Index Fund | 653470 | 1.24% | 2284 | 0.35% | 2019-06-30 |
| T. Rowe Price New Horizons Fund | 631628 | 1.20% | -305053 | -32.57% | 2019-06-30 |
| SPDR | 611533 | 1.16% | 11970 | 2.00% | 2019-07-31 |
| Vanguard Extended Market Index Fund | 607034 | 1.15% | 2581 | 0.43% | 2019-06-30 |
| T. Rowe Price Small-Cap Stock Fund | 570900 | 1.08% | -9400 | -1.62% | 2019-06-30 |
| Wellington Global Health Care Equity | 537835 | 1.02% | 7330 | 1.38% | 2019-03-31 |
| iShares Nasdaq Biotechnology ETF | 520090 | 0.99% | 5382 | 1.05% | 2019-07-30 |
| Fidelity Advisor | 401500 | 0.76% | -18500 | -4.40% | 2019-06-30 |
| Artisan Small Cap Fund | 399967 | 0.76% | 31337 | 8.50% | 2019-06-30 |
| Janus Henderson Global Life Sciences Fd | 394582 | 0.75% | -12157 | -2.99% | 2019-06-30 |
| iShares US Small Cap ETF (CAD-Hedged) | 897142 | 1.70% | -1503 | -0.17% | 2019-05-30 |
| Franklin Biotechnology Discovery Fund | 400477 | 0.76% | -- | -- | 2019-04-30 |
| Vanguard Small Cap Index Fund | 1144383 | 2.17% | 3234 | 0.28% | 2019-04-30 |
| UBS (Lux) EF Biotech (USD) | 325485 | 0.62% | 81268 | 33.28% | 2018-12-31 |
| ZIL Blackrock Global Fds Wld Health Sci | 292007 | 0.56% | -- | -- | 2018-11-30 |
| ZIL Blackrock Glbl Wrd Healthscience USD | 292007 | 0.56% | -- | -- | 2018-11-30 |
| T. Rowe Price Instl Small-Cap Stock Fund | 288000 | 0.56% | 24600 | 9.34% | 2018-12-31 |
| BGF World Healthscience Fund | 292007 | 0.63% | 6100 | 2.13% | 2018-10-31 |
| iShares Russell 2000 Growth ETF | 291746 | 0.63% | 1281 | 0.44% | 2018-12-31 |
| Eventide Gilead Fund | 401000 | 0.87% | -- | -- | 2018-06-30 |
| Pictet-Biotech | 346579 | 0.75% | -86749 | -20.02% | 2017-09-30 |
| Artisan Small Cap Investor | 248792 | 0.54% | 37250 | 17.61% | 2018-06-30 |
| T. Rowe Price Health Sciences | 1331728 | 2.90% | 329593 | 32.89% | 2018-06-30 |
| T. Rowe Price New Horizons | 892035 | 1.95% | 180869 | 25.43% | 2018-06-30 |
| Vanguard Total Stock Mkt Idx | 963545 | 2.09% | -- | -- | 2018-07-31 |
| Eagle Small Cap Growth A | 657640 | 1.43% | -285204 | -30.25% | 2018-06-30 |
| BlackRock Health Sciences Opps Inv A | 651100 | 1.42% | -- | -- | 2018-07-31 |
| iShares Nasdaq Biotechnology | 518680 | 1.04% | -987 | -0.19% | 2018-09-12 |
| Janus Global Life Sciences D | 506877 | 1.11% | 506877 | -- | 2018-06-30 |
| T. Rowe Price Small-Cap Stock | 495600 | 1.08% | -3000 | -0.60% | 2018-06-30 |
| Vanguard Extended Market Idx Inv | 512642 | 1.11% | 3300 | 0.65% | 2018-07-31 |
| Eventide Gilead N | 401000 | 0.87% | -- | -- | 2018-06-30 |
| Goldman Sachs Small/Mid Cap Growth A | 332793 | 0.73% | -- | -- | 2018-06-30 |
| iShares Russell 2000 Growth | 314624 | 0.63% | -303 | -0.10% | 2018-09-12 |
| Vanguard Small Cap Growth Index Inv | 278815 | 0.61% | 3921 | 1.43% | 2018-07-31 |
| T. Rowe Price Instl Small-Cap Stock | 236400 | 0.52% | -- | -- | 2018-06-30 |
| Harbor Small Cap Growth Instl | 250810 | 0.55% | -15610 | -5.86% | 2018-03-31 |
| FIAM Small Company Pool | 250100 | 0.55% | -- | -- | 2018-03-31 |
| Loomis Sayles Small Cap Growth Instl | 202278 | 0.54% | -5474 | -2.63% | 2016-12-31 |
| Oak Ridge Small Cap Growth A | 625000 | 1.66% | -130000 | -17.22% | 2016-11-30 |
| Vanguard Explorer Inv | 533600 | 1.42% | -- | -- | 2016-09-30 |
| Vanguard Explorer Fund | 322000 | 1.00% | -- | -- | 2015-09-30 |
| Fidelity® Select Biotechnology Portfolio | 3222920 | 9.70% | -- | -- | 2015-09-30 |
| iShares Russell 2000 (AU) | 344291 | 1.20% | -432 | -0.10% | 2015-11-19 |
| Fidelity Advisor® Biotechnology Fund | 541641 | 1.60% | -- | -- | 2015-09-30 |
| Fidelity® Select Health Care Portfolio | 569316 | 1.70% | -- | -- | 2015-09-30 |
| Oak Ridge Small Cap Growth Fund | 997499 | 3.00% | 120000 | 13.70% | 2015-08-31 |
| Franklin Biotechnology Discovery | 325277 | 1.00% | -- | -- | 2015-07-31 |
| Sujay R. Kango | Sujay R. Kango is on the board of Cancer Care, Inc. and Chief Commercial Officer & Senior Vice President at Acceleron Pharma, Inc. In the past he occupied the position of Chief Commercial Officer & Executive VP at Infinity Pharmaceuticals, Inc., Vice President-Oncology Global Commercial at AbbVie, Inc., Vice President-Hepatitis Franchise at Merck & Co., Inc. and VP-Global Marketing & Sales Operations at Onyx Pharmaceuticals, Inc. Sujay R. Kango received an MBA, a graduate degree and an undergraduate degree from McNeese State University. |
|---|---|
| Francois Nader | Founder of Jesra Advisors LLC, Francois Nader is a businessperson who has been at the helm of 7 different companies and presently is Chairman for Talaris Therapeutics, Inc., Non-Executive Chairman of Prevail Therapeutics, Inc., Non-Executive Chairman of Acceleron Pharma, Inc., Chief Executive Officer for Jesra Advisors LLC and President at Jesra Foundation, Inc. Dr. Nader is also on the board of 5 other companies. Francois Nader previously occupied the position of Chief Medical Officer at Care Capital LLC, President, Chief Executive Officer & Director at NPS Pharmaceuticals, Inc., Head-Global Commercial Operations at Rhone-Poulenc Basic Chemical Co., Senior VP-Integrated Healthcare Markets at Hoechst Marion Roussel, Inc. and Senior VP-Integrated Healthcare Markets at Aventis Pharmaceuticals, Inc. Francois Nader received an MBA from the University of Tennessee and a doctorate from St. Joseph University. |
| Richard F. Pops | Mr. Richard F. Pops is Independent Director at Neurocrine Biosciences, Inc., Chairman, President & Chief Executive Officer at Alkermes, Inc., Chairman & Chief Executive Officer at Alkermes Plc, a Member at Harvard Medical School, and Strategic Advisor at Longwood Fund Management LLC. He is on the Board of Directors at Reliant Pharmaceuticals LLC, Neurocrine Biosciences, Inc., Acceleron Pharma, Inc., Expressive Constructs, Inc., Biotechnology Industry Organization, New England Healthcare Institute, Pharmaceutical Research & Manufacturers of America, and Epizyme, Inc. Mr. Pops also served on the board at Sirtris Pharmaceuticals, Inc. and CombinatoRx, Inc. Mr. Pops received his undergraduate degree from Stanford University. |
| Kevin F. McLaughlin | Mr. Kevin F. McLaughlin is an Independent Non-Executive Director at Stealth BioTherapeutics Corp., an Independent Director at Vericel Corp. and a Chief Financial Officer, Treasurer & Senior VP at Acceleron Pharma, Inc. He is on the Board of Directors at Stealth BioTherapeutics Corp. and Vericel Corp. Mr. McLaughlin was previously employed as a Chief Financial Officer & Senior Vice President by Qteros, Inc., a Chief Operating Officer & Director by Aptius Education, Inc., a President, Chief Executive Officer & Director by Praecis Pharmaceuticals, Inc., a Treasurer & Vice President by Computervision Corp., a Treasurer & Vice President by Prime Computer, Inc., and a Chief Financial Officer & Vice President by Advanced TechCom, Inc. He received his undergraduate degree from Northeastern University and an MBA from Babson College. |
| Richard F. Pops | Mr. Richard F. Pops is Independent Director at Neurocrine Biosciences, Inc., Chairman, President & Chief Executive Officer at Alkermes, Inc., Chairman & Chief Executive Officer at Alkermes Plc, a Member at Harvard Medical School, and Strategic Advisor at Longwood Fund Management LLC. He is on the Board of Directors at Reliant Pharmaceuticals LLC, Neurocrine Biosciences, Inc., Acceleron Pharma, Inc., Expressive Constructs, Inc., Biotechnology Industry Organization, New England Healthcare Institute, Pharmaceutical Research & Manufacturers of America, and Epizyme, Inc. Mr. Pops also served on the board at Sirtris Pharmaceuticals, Inc. and CombinatoRx, Inc. Mr. Pops received his undergraduate degree from Stanford University. |
| Terrence C. Kearney | Terrence C. Kearney is on the board of Vertex Pharmaceuticals, Inc., Acceleron Pharma, Inc. and Levo Therapeutics, Inc. In his past career he held the position of Treasurer & Vice President of Abbott Laboratories and Chief Operating Officer of Hospira, Inc. Terrence C. Kearney received an undergraduate degree from the University of Illinois and an MBA from the University of Denver. |
| Jean M. George | Founder of Genzyme Tissue Repair, Jean M. George currently holds the position of General Partner of Lightstone Ventures, Managing Director at LSV Capital Management LLC (a subsidiary of Lightstone Ventures) and General Partner for Advanced Technology Ventures, Managing Director at ATV Associates VII LLC (a subsidiary of Advanced Technology Ventures). Ms. George is also Managing Director at LSV Capital Management LLC and Managing Director at ATV Associates VII LLC and on the board of 9 other companies. In the past Jean M. George occupied the position of Director at NeuroMetrix, Inc., Director at ZELTIQ Aesthetics, Inc., Director at Bioverativ Therapeutics, Inc., Director at Microbia, Inc., Vice President at Genzyme Tissue Repair, Director at NuGenesis Technologies Corp., Director at BancBoston Capital, Inc. and Vice President-Sales & Marketing for Genzyme Corp. She received an undergraduate degree from the University of Maine and an MBA from Simmons School of Management. |
| Matthew L. Sherman | Dr. Matthew L. Sherman, MD, is an Independent Director at Pulmatrix, Inc. and a Chief Medical Officer & Executive Vice President at Acceleron Pharma, Inc. He is on the Board of Directors at NewLink Genetics Corp. and Pulmatrix, Inc. Dr. Sherman was previously employed as a Chief Medical Officer & Senior Vice President by Synta Pharmaceuticals Corp., an Assistant Clinical Professor by Harvard Medical School, an Assistant Clinical Professor by Dana-Farber Cancer Institute, Inc., a Therapeutic Area Director-Oncology by Genetics Institute LLC, a Professor by The Brigham & Women's Hospital, Inc., a Member by The Marine Biological Laboratory, and a Therapeutic Area Director-Oncology by Wyeth Pharmaceuticals LLC. He received his undergraduate degree from Massachusetts Institute of Technology and a doctorate degree from Dartmouth Medical School. |
| Joseph S. Zakrzewski | Joseph S. Zakrzewski is a businessperson who has been at the head of 6 different companies. Mr. Zakrzewski holds the position of Executive Chairman of Thrasos Therapeutics, Inc. He is also on the board of 10 other companies. Mr. Zakrzewski previously occupied the position of Non-Executive Chairman at Onxeo SA, Chairman for Promedior, Inc., Vice President-Corporate Business Development at Eli Lilly & Co., Chairman & Chief Executive Officer of Amarin Pharmaceuticals, Inc., Chairman, President & Chief Executive Officer at Xcellerex, Inc., Chief Operating Officer for Reliant Pharmaceuticals LLC and Venture Partner at OrbiMed Advisors Private Equity. Mr. Zakrzewski received an MBA from Indiana University and a graduate degree and an undergraduate degree from Drexel University. |
| Todd James | Presently, Todd James occupies the position of VP-Investor Relations & Corporate Communications at Acceleron Pharma, Inc. In the past Mr. James was Vice President at Trout Capital LLC. Mr. James received an undergraduate degree from Moravian College. |
| George S. Golumbeski | Dr. George S. Golumbeski is an Independent Director at Enanta Pharmaceuticals, Inc., an Independent Director at Acceleron Pharma, Inc. and a Chairman at BioSight Ltd. He is on the Board of Directors at MorphoSys AG, Enanta Pharmaceuticals, Inc., Acceleron Pharma, Inc., National Audubon Society, Inc., Tizona Therapeutics, Inc., BioNJ, Inc. and Keck Graduate Institute of Applied Life Sciences. Dr. Golumbeski was previously employed as an Executive Vice President-Business Development by Celgene Corp., a Chief Executive Officer by Nabriva Therapeutics AG, a Vice President-Business Development by Elan Pharmaceuticals, Inc., a VP-Business Development, Licensing & Strategy by Novartis Oncology, Inc., and a Vice President-Corporate Development by SCHWARZ PHARMA, Inc. He received his undergraduate degree from the University of Virginia and a doctorate degree from the University of Wisconsin. |
| Thomas A. McCourt | Thomas A. McCourt founded Astra Merck, Inc. Presently, Mr. McCourt is President at Ironwood Pharmaceuticals, Inc. He is also on the board of Acceleron Pharma, Inc. Mr. McCourt previously was Brand Manager-Prilosec at Astra Merck, Inc. and Vice President-Strategic Marketing & Operations at Novartis Corp. Mr. McCourt received an undergraduate degree from the University of Wisconsin. |
| James V. Desiderio | Presently, James V. Desiderio occupies the position of Vice President-Regulatory Affairs at Acceleron Pharma, Inc. He previously held the position of Principal at Gilead Sciences, Inc., Principal at Bristol-Myers Squibb Co. and Executive Director & Head-Program Management at Idenix Pharmaceuticals LLC. Dr. Desiderio received an undergraduate degree from Long Island University and a graduate degree and an undergraduate degree from College of Veterinary Medicine. |
| John D. Quisel | Presently, John D. Quisel is Chief Business Officer & Executive Vice President at Acceleron Pharma, Inc. In the past he was Principal at Ropes & Gray LLP and Principal at Foley Hoag LLP. He received a graduate degree from Stanford University, a doctorate from Massachusetts Institute of Technology, an undergraduate degree from Harvard University and a graduate degree from Harvard Law School. |
| John D. Quisel | Presently, John D. Quisel is Chief Business Officer & Executive Vice President at Acceleron Pharma, Inc. In the past he was Principal at Ropes & Gray LLP and Principal at Foley Hoag LLP. He received a graduate degree from Stanford University, a doctorate from Massachusetts Institute of Technology, an undergraduate degree from Harvard University and a graduate degree from Harvard Law School. |
| Ravindra Kumar | Ravindra Kumar is Chief Scientific Officer & Senior Vice President at Acceleron Pharma, Inc. In his past career Dr. Kumar held the position of Senior Scientist at Wyeth Pharmaceuticals LLC and Principal Scientist at Genetics Institute LLC. Dr. Kumar received a doctorate from the University of New Brunswick, a graduate degree from Chaudhary Charan Singh University and an undergraduate degree from Mahatma Jyotiba Phule Rohilkhand University. |
| Christopher Rovaldi | Christopher Rovaldi is SVP-Program Management & Operations at Acceleron Pharma, Inc. In the past he held the position of Director-Project Management at Idenix Pharmaceuticals LLC, Senior Research Associate at Periodontix, Inc. and Director-Project Management at Cubist Pharmaceuticals, Inc. Mr. Rovaldi received a graduate degree and an undergraduate degree from the University of New Hampshire. |
| Sujay R. Kango | Sujay R. Kango is on the board of Cancer Care, Inc. and Chief Commercial Officer & Senior Vice President at Acceleron Pharma, Inc. In the past he occupied the position of Chief Commercial Officer & Executive VP at Infinity Pharmaceuticals, Inc., Vice President-Oncology Global Commercial at AbbVie, Inc., Vice President-Hepatitis Franchise at Merck & Co., Inc. and VP-Global Marketing & Sales Operations at Onyx Pharmaceuticals, Inc. Sujay R. Kango received an MBA, a graduate degree and an undergraduate degree from McNeese State University. |
| Karen L. Smith | Presently, Karen L. Smith holds the position of President & Chief Executive Officer at Medeor Therapeutics, Inc. Dr. Smith is also on the board of Antares Pharma, Inc., Sangamo Therapeutics, Inc., Acceleron Pharma, Inc. and Sucampo Pharmaceuticals, Inc. In her past career Dr. Smith held the position of Chief Medical Officer & EVP-Research & Development at Jazz Pharmaceuticals Plc and Director & Vice President at Celator Pharmaceuticals, Inc. (a subsidiary of Jazz Pharmaceuticals Plc), Head-US Clinical Operations at Bristol-Myers Squibb Co., Chief Executive Officer at Boron Molecular Ltd., SVP-Global Medical Affairs & Head-Dermatology at Allergan, Inc. and Head-External Medical Relations at AstraZeneca LP. Karen L. Smith received a doctorate from the University of Warwick, a doctorate from The University of Western Australia, an MBA from the University of New England (Australia), a graduate degree from the University of Salford and an undergraduate degree from Curtin University of Technology. |
| Habib J. Dable | Presently, Habib J. Dable is President, Chief Executive Officer & Director at Acceleron Pharma, Inc. He is also on the board of Millendo Therapeutics US, Inc. and Millendo Therapeutics, Inc. In the past Mr. Dable was President-US Pharmaceuticals at Bayer AG and EVP & Global Head- Specialty Medicine at Bayer HealthCare Pharmaceuticals, Inc. (a subsidiary of Bayer AG). He received an MBA and an undergraduate degree from the University of New Brunswick. |
| Karen L. Smith | Presently, Karen L. Smith holds the position of President & Chief Executive Officer at Medeor Therapeutics, Inc. Dr. Smith is also on the board of Antares Pharma, Inc., Sangamo Therapeutics, Inc., Acceleron Pharma, Inc. and Sucampo Pharmaceuticals, Inc. In her past career Dr. Smith held the position of Chief Medical Officer & EVP-Research & Development at Jazz Pharmaceuticals Plc and Director & Vice President at Celator Pharmaceuticals, Inc. (a subsidiary of Jazz Pharmaceuticals Plc), Head-US Clinical Operations at Bristol-Myers Squibb Co., Chief Executive Officer at Boron Molecular Ltd., SVP-Global Medical Affairs & Head-Dermatology at Allergan, Inc. and Head-External Medical Relations at AstraZeneca LP. Karen L. Smith received a doctorate from the University of Warwick, a doctorate from The University of Western Australia, an MBA from the University of New England (Australia), a graduate degree from the University of Salford and an undergraduate degree from Curtin University of Technology. |
| Adam M. Veness | Presently, Adam M. Veness occupies the position of Secretary, Vice President & General Counsel for Acceleron Pharma, Inc. |
| Kevin McManus | Mr. Kevin McManus is a Chief Human Resources Officer at Acceleron Pharma, Inc. He received his undergraduate degree from Cornell University. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 1
【Acceleron肺高压药物试验达到主要目标 股价一度暴涨79%】美国制药商Acceleron Pharma周一表示，其肺动脉高压(PAH)药物sotatercept在中期试验中达到了主要目标，推动其股价盘中一度暴涨79%，收盘上涨66%。肺动脉高压是一种罕见疾病，发作时患者肺部的动脉收缩，迫使心脏更努力工作，往往导致心力衰竭。目前这种疾病无法治愈，但市场上有能够控制病情的治疗药物。